{"id":"NCT01449682","sponsor":"Retina Macula Institute","briefTitle":"Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.","officialTitle":"Efficacy of an Intravitreal Dexamethasone Implant on Macular Function in Retinal Vein Occlusion Following Treatment With Intravitreal Anti-VEGF Injections.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2012-07","completion":"2013-02","firstPosted":"2011-10-10","resultsPosted":"2017-05-31","lastUpdate":"2017-05-31"},"enrollment":10,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Retinal Vein Occlusion","Macular Edema"],"interventions":[{"type":"DRUG","name":"Ozurdex","otherNames":["Dexamethasone implant, DEX implant"]},{"type":"DRUG","name":"Ozurdex","otherNames":["dexamethasone implant, DEX implant"]}],"arms":[{"label":"Ozurdex PRN","type":"ACTIVE_COMPARATOR"},{"label":"Ozurdex Q16 weeks","type":"ACTIVE_COMPARATOR"}],"summary":"To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (OzurdexÂ®) on macular function and recalcitrant macular edema associated with retinal vein occlusion following treatment with 2 or more prior intravitreal anti-VEGF drug injections.","primaryOutcome":{"measure":"Macular Function Using Microperimetry","timeFrame":"baseline to 48 weeks","effectByArm":[{"arm":"Ozurdex PRN","deltaMin":2.7,"sd":0.8},{"arm":"Ozurdex Q16 Weeks","deltaMin":12.7,"sd":2.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":5},"commonTop":["Elevated Intraocular Pressure"]}}